EGFR
Epidermal growth factor receptor; ErbB-1; HER1
The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.
EGFR Isoform Specific Products
All Product Categories
-
EGFR Inhibitors
(1038)
View all products
-
EGFR Agonists
(4)
View all products
-
EGFR Antagonists
(5)
View all products
-
EGFR Activators
(8)
View all products
-
EGFR Modulators
(7)
View all products
-
EGFR Chemicals
(3)
View all products
-
EGFR Inducers
(4)
View all products
-
EGFR Degraders
(45)
View all products
-
EGFR Controls
(6)
View all products
-
EGFR Substrate
(1)
View all products
-
EGFR Ligands
(19)
View all products
-
ErbB2/HER2 Proteins
(39)
View all products
-
ErbB3/HER3 Proteins
(15)
View all products
-
EGFR Proteins
(46)
View all products
-
ErbB4/HER4 Proteins
(10)
View all products
-
EGFR Related Products (1262)
Related Products (1262)
-
Recombinant Proteins (110)
-
Antibodies (19)
-
EGFR Isoform Comparison
-
KU004
0 ImagesCat. No.: HY-164489CAS No.: 1260401-93-1KU004 is a potent dual EGFR/HER2 inhibitor with anticancer effects. KU004 inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR and downstream Akt and Erk pathways and induces cell Apoptosis mainly via the extrinsic pathway. KU004 is a quinazoline derivative.
-
Len-604
0 ImagesCat. No.: HY-182817Len-604 is a FGFR inhibitor with IC50 values of 9.71 nM, 9.93 nM, 29.80 nM and 14.48 nM against FGFR4, FGFR1, FGFR2 and FGFR3, respectively. Len-604 reduces the phosphorylation levels of FGFR4 and ERK, and induces DNA damage and apoptosis in cancer cells. Len-604 is applicable to research related to liver cancer.
-
Erlotinib-13C6
0 ImagesCat. No.: HY-50896S1CAS No.: 1211107-68-4Synonyms: CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6Erlotinib-13C6 (CP-358774-13C6) is the 13C-labeled Erlotinib (HY-50896). Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
-
EGFR T790M Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70709EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR T790M Recombinant Human Active Protein Kinase is a recombinant EEGFR T790M protein that can be used to study EGFR T790M-related functions.
-
Nelipepimut-S
0 ImagesCat. No.: HY-106204CAS No.: 160212-35-1Synonyms: E75Nelipepimut-S (E75) is a peptide vaccine targeting HER2. When used in combination with granulocyte-macrophage colony-stimulating factor, Nelipepimut-S stimulates immune activity and induces anti-HER2 immune responses. Nelipepimut-S can be used in research related to breast cancer, triple-negative breast cancer and ductal carcinoma in situ.
-
UNC-CA359
0 ImagesCat. No.: HY-150782CAS No.: 2676156-05-9UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC50 value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research. UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Hsp90-IN-42
0 ImagesCat. No.: HY-176279Hsp90-IN-42 is a heat shock protein 90 (Hsp90) inhibitor with an IC50 of 15.65 nM against human targets. Hsp90-IN-42 destabilizes EGFR and inhibits the activation of the EGFR-Akt signaling pathway. Hsp90-IN-42 suppresses the proliferation and migration of cancer cells, induces cell cycle arrest by downregulating CDK12 and CDK13, and triggers mild apoptosis via downregulating Bcl-2 and upregulating Bax. Hsp90-IN-42 inhibits tumor growth in xenograft mouse models. Hsp90-IN-42 can be used in research related to colorectal cancer.
-
Antiproliferative agent-49
0 ImagesCat. No.: HY-158016Antiproliferative agent-49 (Compound 5a) is a EGFR-TK inhibitor with an IC50 of 0.09 μM. Antiproliferative agent-49 is a anti-proliferative agent. Antiproliferative agent-49 displays good activities against HER3 and HER4 with IC50 values 0.18 and 0.37 µM. Antiproliferative agent-49 induces mitochondrial apoptotic pathway and increased accumulation of ROS.
-
Gefitinib N-oxide hydrochloride
0 ImagesCat. No.: HY-100636AGefitinib N-oxide hydrochloride is the N-oxide derivative of Gefitinib. Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells.
-
EGFR-IN-79
0 ImagesCat. No.: HY-155074CAS No.: 3049072-04-7EGFR-IN-79 (compound 21) is an EGFR inhibior with antitumor activity. EGFR-IN-79 induces ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy. EGFR-IN-79 induces cell death at both proliferating and quiescent zones of EJ28 spheroids. EGFR-IN-79 exhibits safety profile in the zebrafish-based model.
-
Anti-Epiregulin Antibody
0 ImagesCat. No.: HY-P991986Anti-Epiregulin Antibody is an anti-Epiregulin antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
-
EGFR-IN-173
0 ImagesCat. No.: HY-175864EGFR-IN-173 is an orally active, pan-mutant EGFR tyrosine kinase inhibitor that targets EGFR 19del, L858R/T790M and C797S triple-mutations, potently inhibiting EGFR19del/T790M/C797S with an IC50 of 1.19 nM while showing over 100-fold selectivity for mutant over wild-type EGFR (IC50 = 19.362 μM against WT). EGFR-IN-173 significantly inhibits cell migration, induces apoptosis in non-small cell lung cancer (NSCLC) cells. EGFR-IN-173 inhibits EGFR phosphorylation and suppresses the downstream pathways (MAPK/ERK, AKT, STAT3). EGFR-IN-173 exhibits antitumor efficacy in NSCLC and Ba/F3 xenograft models. EGFR-IN-173 can be used for NSCLC research.
-
EGFR T790M/L858R-IN-9
0 ImagesCat. No.: HY-170665EGFR T790M/L858R-IN-9 (Compound 8) is an EGFR-L858R/T790M inhibitor that demonstrates potent inhibitory phosphorylation effects against the EGFR-L858R/T790M mutant kinase, with an IC50 value of 0.0064µM. EGFR T790M/L858R-IN-9 also inhibits the proliferation of non-small cell lung cancer (NSCLC) cells and can be utilized in cancer research.
-
KHK-2866
0 ImagesKHK-2866 is a recombinant humanized monoclonal antibody targeting heparin-binding epidermal growth factor-like growth factor (HB-EGF). The predicted molecular weight (MW) of KHK-2866 is 147.68 kDa. KHK-2866 can be used for tumor research.
-
HER4/HER2-IN-1
0 ImagesCat. No.: HY-178119HER4/HER2-IN-1 (Compound 4b) is a HER4/HER2 inhibitor. HER4/HER2-IN-1 inhibits the proliferation of HER2-positive cells. HER4/HER2-IN-1 reduces the total expression level of HER2 in A431 cells, while the phosphorylated HER2 (p-HER2) does not decrease. HER4/HER2-IN-1 lowers the level of cell cycle protein D1 (cyclin D1) and stimulates the cleavage of PARP. HER4/HER2-IN-1 can be used for the study of cancer, such as breast cancer.
-
EGFR/HDAC-IN-2
0 ImagesCat. No.: HY-175805EGFR/HDAC-IN-2 (Compound 38) is dual-functional inhibitor of EGFR and HDAC3 with IC50s of 20.34 and 1.09 nM for CDK9 and HDAC3, respectively. EGFR/HDAC-IN-2 has superior anti-proliferative activity against cancer cells, inhibits cell migration and induces late-stage cell apoptosis. EGFR/HDAC-IN-2 significantly inhibits triple-negative breast cancer (TNBC) tumor growth in xenograft mouse models. EGFR/HDAC-IN-2 can be used for cancers like TNBC research.
